MuratOsmanArcasoyMD

Oncology • Durham, NC

Associate Professor, Medicine, Duke University School of Medicine

Join to view full profile

Dr. Arcasoy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arcasoy's full profile

Already have an account?

Office
Duke University Medical Center
Box 3912 Dumc
Durham, NC 27710
Phone+1 919-668-6309

Fax+1 919-681-6160

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1988 - 1992
Ege Univ- Fac MedClass of 1987

Certifications & Licensure

NC State Medical License 1999 - 2025
CT State Medical License 1990 - 2000
NY State Medical License 1991 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Elected Member The American Society for Clinical Investigation, 2009

Clinical Trials

Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed

Publications & Presentations

PubMed

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Sandy El Bitar, Murat O Arcasoy
Clinical Advances in Hematology & Oncology. 2024-03-01
2 citations
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Dawn Maze, Murat O Arcasoy, Ryan Henrie, Sonia Cerquozzi, Rammurti Kamble
Bone Marrow Transplantation. 2024-02-01
Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Dawn Maze, Murat O Arcasoy, Ryan Henrie, Sonia Cerquozzi, Rammurti Kamble
Bone Marrow Transplantation. 2024-02-01

Abstracts/Posters

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Murat O. Arcasoy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Grant Support

Erythropoietin Receptors In Breast CancerNational Cancer Institute2004–2008
Role Of Erythropoietin Receptor Signaling In HeartNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
Erythropoietin Receptor Regulation Of ErythropoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002
Erythropoietin Receptor Regulation Of ErythropoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1998–1999